ICCM

ICCM

USD

IceCure Medical Ltd. Ordinary Shares

$0.728+0.000 (0.069%)

Echtzeitkurs

Healthcare
Medizinprodukte
Israel

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$0.728

Hoch

$0.740

Tief

$0.714

Volumen

0.13M

Unternehmensfundamentaldaten

Marktkapitalisierung

50.2M

Branche

Medizinprodukte

Land

Israel

Handelsstatistiken

Durchschnittliches Volumen

1.68M

Börse

NCM

Währung

USD

52-Wochen-Spanne

Tief $0.534Aktuell $0.728Hoch $1.66

Ähnliche Nachrichten

PR Newswire

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...

Mehr anzeigen
IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Icecure Medical, Raises Price Target to $2.5

HC Wainwright & Co. analyst Yi Chen maintains Icecure Medical with a Buy and raises the price target from $2 to $2.5.

Mehr anzeigen
HC Wainwright & Co. Maintains Buy on Icecure Medical, Raises Price Target to $2.5
PR Newswire

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

The U.S. Food and Drug Administration ("FDA") has granted marketing authorization for ProSense®, a minimally invasive cryoablation treatment for...

Mehr anzeigen
IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care
PR Newswire

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...

Mehr anzeigen
IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above